Janku F - Search Results

1

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.

Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Tsimberidou AM, et al. Among authors: janku f. Clin Cancer Res. 2012 Nov 15;18(22):6373-83. doi: 10.1158/1078-0432.CCR-12-1627. Epub 2012 Sep 10. Clin Cancer Res. 2012. PMID: 22966018 Free PMC article.

2

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Dittrich C, Petruzelka L, Vodvarka P, Gneist M, Janku F, Kysela T, Melemed A, Latz J, Simms L, Krejcy K. Dittrich C, et al. Among authors: janku f. Clin Cancer Res. 2006 Dec 1;12(23):7071-8. doi: 10.1158/1078-0432.CCR-05-2829. Clin Cancer Res. 2006. PMID: 17145830 Clinical Trial.

3

Adjuvant interferon in high-risk melanoma: end of the era?

Janku F, Kurzrock R. Janku F, et al. J Clin Oncol. 2010 Jan 10;28(2):e15-6; author reply e17-8. doi: 10.1200/JCO.2009.24.9326. Epub 2009 Nov 30. J Clin Oncol. 2010. PMID: 19949007 No abstract available.

4

Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra).

El-Osta H, Janku F, Kurzrock R. El-Osta H, et al. Among authors: janku f. Mol Cancer Ther. 2010 Jun;9(6):1485-8. doi: 10.1158/1535-7163.MCT-10-0156. Epub 2010 May 25. Mol Cancer Ther. 2010. PMID: 20501803 Free PMC article.

5

Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment.

Garrido-Laguna I, Janku F, Falchook GS, Fu S, Hong DS, Naing A, Aaron J, Wang X, Kies M, Kurzrock R. Garrido-Laguna I, et al. Among authors: janku f. Clin Cancer Res. 2010 Aug 1;16(15):4031-7. doi: 10.1158/1078-0432.CCR-10-0672. Epub 2010 Jun 4. Clin Cancer Res. 2010. PMID: 20525754

6

Targeted therapy in non-small-cell lung cancer--is it becoming a reality?

Janku F, Stewart DJ, Kurzrock R. Janku F, et al. Nat Rev Clin Oncol. 2010 Jul;7(7):401-14. doi: 10.1038/nrclinonc.2010.64. Epub 2010 Jun 15. Nat Rev Clin Oncol. 2010. PMID: 20551945 Review.

7

Response of histiocytoses to imatinib mesylate: fire to ashes.

Janku F, Amin HM, Yang D, Garrido-Laguna I, Trent JC, Kurzrock R. Janku F, et al. J Clin Oncol. 2010 Nov 1;28(31):e633-6. doi: 10.1200/JCO.2010.29.9073. Epub 2010 Aug 23. J Clin Oncol. 2010. PMID: 20733125 No abstract available.

8

PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.

Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. Janku F, et al. Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7. Mol Cancer Ther. 2011. PMID: 21216929 Free PMC article.

9

Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic.

Janku F, Tsimberidou AM, Wang X, Hong DS, Naing A, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Janku F, et al. Oncologist. 2011;16(3):327-35. doi: 10.1634/theoncologist.2010-0308. Epub 2011 Feb 21. Oncologist. 2011. PMID: 21339262 Free PMC article.

10

Autophagy as a target for anticancer therapy.

Janku F, McConkey DJ, Hong DS, Kurzrock R. Janku F, et al. Nat Rev Clin Oncol. 2011 May 17;8(9):528-39. doi: 10.1038/nrclinonc.2011.71. Nat Rev Clin Oncol. 2011. PMID: 21587219 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

293 results

Search Page